Managers / Q4 2019 · view latest →
MASO CAPITAL PARTNERS Ltd
CIK 0001698093 · 8/F PRINTING HOUSE, 6 DUDDELL STREET, HONG KONG, 000000 · 852 34686200
Summary
Maso Capital Partners Ltd reported $311M in U.S.-listed holdings across 20 positions for Q4 2019.
The portfolio is heavily concentrated: Allergan alone accounts for 20.8% of reported value.
Compared with Q3 2019, the fund opened 7 new positions and exited 6.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Other · 53.2% · $165M
- ADR · 28.8% · $90M
- Common Stock · 18.1% · $56M
Quarter-over-Quarter Changes full breakdown →
vs Q3 2019 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| ZAYO GROUP HLDGS INC | NEW | +646.3K | 646.3K | +$22M | $22M |
| ALIBABA GROUP HLDG LTD | NEW | +820 | 820 | +$17M | $17M |
| NEW FRONTIER HEALTH CORP | NEW | +700.0K | 700.0K | +$7M | $7M |
| SEA LTD | NEW | +2.00M | 2.00M | +$2M | $2M |
| CLVTCLARIVATE ANALYTICS PLC | NEW | +50.0K | 50.0K | +$840,000 | $840,000 |
| AUDENTES THERAPEUTICS INC | NEW | +2.3K | 2.3K | +$136,000 | $136,000 |
| NAKED BRAND GROUP LIMITED | NEW | +21.2K | 21.2K | +$33,000 | $33,000 |
| CHINA BIOLOGIC PRODS HLDGS INC | ADDED | +316.2K | 539.6K | +$37M | $63M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2019
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | ALLERGAN PLC | SHS | 20.76% | $65M | 337.7K |
| 2 | CHINA BIOLOGIC PRODS HLDGS INC | COM | 20.19% | $63M | 539.6K |
| 3 | BITAUTO HLDGS LTD | SPONSORED ADS | 15.16% | $47M | 3.18M |
| 4 | CHANGYOU COM LTD | ADS REP CL A | 9.48% | $29M | 3.01M |
| 5 | ZAYO GROUP HLDGS INC | COM | 7.20% | $22M | 646.3K |
| 6 | GNWGENWORTH FINL INChistory → | COM CL A | 5.09% | $16M | 3.60M |
| 7 | BUNGE LIMITED | COM | 3.65% | $11M | 197.0K |
| 8 | ACHCACADIA HEALTHCARE COMPANY INChistory → | COM | 3.00% | $9M | 281.1K |
| 9 | YUMCYUM CHINA HLDGS INChistory → | COM | 2.45% | $8M | 158.4K |
| 10 | NEW FRONTIER HEALTH CORP | ORD SHS | 2.25% | $7M | 700.0K |
| 11 | SOHUSOHU COM LTDhistory → | SPONSORED ADS | 1.38% | $4M | 384.0K |
| 12 | TAKTAKEDA PHARMACEUTICAL CO LTDhistory → | SPONSORED ADS | 1.15% | $4M | 181.6K |
| 13 | MLCOMELCO RESORTS AND ENTMT LTDhistory → | ADR | 1.07% | $3M | 137.2K |
| 14 | SEA LTD | DEBT | 0.69% | $2M | 2.00M |
| 15 | HCMHUTCHISON CHINA MEDITECH LTD | SPONSORED ADR | 0.56% | $2M | 69.0K |
| 16 | CLVTCLARIVATE ANALYTICS PLC | COM | 0.27% | $840,000 | 50.0K |
| 17 | AUDENTES THERAPEUTICS INC | COM | 0.04% | $136,000 | 2.3K |
| 18 | NAKED BRAND GROUP LIMITED | SHS NEW | 0.01% | $33,000 | 21.2K |
| 19 | BABAALIBABA GROUP HLDG LTD | SPONSORED ADS | 0.00% | $13,000 | 60 |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2025 | $61M | 44 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $57M | 29 | Aug 18, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $66M | 34 | May 9, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $79M | 34 | Feb 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $107M | 36 | Nov 4, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | Under review | 28 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $135,260 | 36 | May 10, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $115,713 | 27 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $183,560 | 37 | Nov 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $228,000 | 37 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $150,581 | 36 | May 11, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | Under review | 42 | Feb 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022REVEALED | $429M | 60 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $177M | 61 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $246M | 56 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $218M | 47 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $222M | 41 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $304M | 54 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $260M | 47 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $367M | 45 | Feb 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $179M | 21 | Nov 12, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $248M | 22 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $386M | 21 | May 11, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $311M | 20 | Feb 12, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $278M | 19 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $191M | 19 | Aug 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $145M | 16 | May 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $80M | 10 | Feb 14, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.